{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:01:19Z","timestamp":1775311279165,"version":"3.50.1"},"reference-count":17,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Hereditary transthyretin amyloidosis (ATTRv; v for \u201cvariant\u201d) is the most common form of hereditary amyloidosis, with an autosomal dominant inheritance and a variable penetrance. This disease has a significant variability in clinical presentation and multiorgan involvement. While kidney involvement in early-onset ATTRv has been reported in one-third of patients, in late-onset ATTRv it has generally been considered rare. In the present study, we describe trajectories of kidney function over time before and after treatment with gene silencing therapies in a cohort of 17 ATTRv patients with different mutations, coming from Italy (nine subjects treated with inotersen and eight patients treated with patisiran). The analysis of estimated glomerular filtration rate (eGFR) slopes revealed that the average change in eGFR was 0.01 mL\/min\/1.73 m2 per month before initiation and \u22120.23 mL\/min\/1.73 m2 per month during follow-up for inotersen and \u22120.62 mL\/min\/1.73 m2 per month before initiation and \u22120.20 mL\/min\/1.73 m2 per month during follow-up for patisiran. In conclusion, we did not observe any significant difference either between the two groups of treatment or within-group before and after therapy, so gene-silencing therapies may be considered safe for renal function in ATTRv and are not associated with a worsening of eGFR slope.<\/jats:p>","DOI":"10.3390\/genes13122236","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T01:42:02Z","timestamp":1669686122000},"page":"2236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trajectories of Kidney Function in Patients with ATTRv Treated with Gene Silencers"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-505X","authenticated-orcid":false,"given":"Marco","family":"Luigetti","sequence":"first","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, 00168 Roma, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-5988","authenticated-orcid":false,"given":"Valeria","family":"Guglielmino","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-1509","authenticated-orcid":false,"given":"Angela","family":"Romano","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Neurologia, 00168 Roma, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-0320","authenticated-orcid":false,"given":"Maria Ausilia","family":"Sciarrone","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-1575","authenticated-orcid":false,"given":"Francesca","family":"Vitali","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-5262","authenticated-orcid":false,"given":"Viola","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore, 00168 Roma, Italy"},{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Nefrologia, 00168 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15403\/jgld-2474","article-title":"Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: A Single-Centre Experience","volume":"29","author":"Luigetti","year":"2020","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Said","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10072-012-1105-y","article-title":"TTR-related amyloid neuropathy: Clinical, electrophysiological and pathological findings in 15 unrelated patients","volume":"34","author":"Luigetti","year":"2013","journal-title":"Neurol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ferraro, P.M., D\u2019Ambrosio, V., Di Paolantonio, A., Guglielmino, V., Calabresi, P., Sabatelli, M., and Luigetti, M. (2021). Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience. Brain Sci., 11.","DOI":"10.3390\/brainsci11080980"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio, V., Ferraro, P.M., Guglielmino, V., and Luigetti, M. (2022). Kidney involvement in hereditary transthyretin amyloidosis: Is there a role for cystatin C?. Clin. Kidney J., sfac156.","DOI":"10.1093\/ckj\/sfac156"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dang, J., Segaux, L., Moktefi, A., Stehl\u00e9, T., Kharoubi, M., El Karoui, K., R\u00e9my, P., Grimbert, P., Plante-Bordeneuve, V., and Guendouz, S. (2022). Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: A French observational study. Amyloid, 1\u201311.","DOI":"10.1080\/13506129.2022.2098011"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/13506129.2019.1583186","article-title":"Significant reduction in proteinuria after treatment with tafamidis","volume":"26","author":"Ripoll","year":"2019","journal-title":"Amyloid"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1080\/13506129.2016.1277697","article-title":"Transthyretin (ATTR) amyloidosis nephropathy: Lessons from a TTR stabilizer molecule","volume":"24","author":"Rocha","year":"2017","journal-title":"Amyloid"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/ene.15325","article-title":"Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy","volume":"29","author":"Luigetti","year":"2022","journal-title":"Eur. J. Neurol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/12\/2236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:28:51Z","timestamp":1760146131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/12\/2236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["genes13122236"],"URL":"https:\/\/doi.org\/10.3390\/genes13122236","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}